1418142-73-0

Upstream product

• 13526-66-4 3-bromo-6-chloro-imidazo[1,2-b]pyridazine 
• 63503-60-6 3-chlorophenylboronic acid 
• 928336-86-1 6-chloro-3-(3-chlorophenyl)imidazo[1,2-b]pyridazine 
• 854443-96-2 4-aminocyclohexane-1-sulfonamide 
• 104618-31-7 trans-2-(4-hydroxycyclohexyl)-1H-isoindole-1,3(2H)-dione 
• 1418143-13-1 S-(4-(1,3-dioxoisoindolin-2-yl)cyclohexyl)ethanethioate 
• 1418143-14-2 4-(1,3-dioxoisoindolin-2-yl)cyclohexane-1-sulfonic acid 
• 1418143-15-3 4-(1,3-dioxoisoindolin-2-yl)cyclohexane-1-sulfonyl chloride 
• 1418143-16-4 4-(1,3-dioxoisoindolin-2-yl)cyclohexane-1-sulfonamide 

Relevant academic research and scientific papers

Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

HETEROCYCLIC PROTEIN KINASE INHIBITORS

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.